EIF4EBP1 and acute myeloid leukemia: Importantly, the combined treatment with GDC-0941 and AZD1208 reduced the expression levels of Mcl-1 more distinctively as compared with treatment with either of these inhibitors alone only in FLT3-ITD-positive primary AML cells (Case 1-3), which correlated to some extent with the inhibitory effects on phosphorylation of 4EBP1 and on viable cell numbers.